GlassScriptPhysician profile
Eric L Bandy
NPI 1881695815
$1,785.03
in general payments reported to CMS, 2019-2025
22 companies · $146 in 2025
The $146 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $362 · 2020: $315 · 2021: $289 · 2022: $250 · 2023: $238 · 2024: $185 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $569.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $568.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $583.51 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $179.05 | 2019-2025 | |
| Lilly USA, LLC | $158.97 | 2020-2024 | Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $146.50 | 2021-2024 | |
| Amarin Pharma, INC. | $120.12 | 2020-2021 | |
| Astellas Pharma US INC | $109.13 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $104.92 | 2019-2023 | Farxiga |
| Xeris Pharmaceuticals, INC. | $80.60 | 2023-2024 | Gvoke Hypopen |
| Amgen INC. | $38.25 | 2019-2025 | Evenity, Prolia |
| Allergan, INC. | $28.92 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $27.32 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $25.76 | 2022 | |
| Esperion Therapeutics, INC. | $25.59 | 2020-2022 | |
| Daiichi Sankyo INC. | $24.22 | 2024 | Injectafer |
| Medtronic, INC. | $22.17 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $21.01 | 2022 | |
| Axsome Therapeutics, INC. | $17.49 | 2025 | Auvelity |
| Inspire Medical Systems, INC. | $15.26 | 2025 | Inspire |
| Corcept Therapeutics | $15.08 | 2024 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.93 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $13.92 | 2023 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $13.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Bandy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.